gptkbp:instance_of
|
gptkb:chemical_compound
|
gptkbp:bfsLayer
|
6
|
gptkbp:bfsParent
|
gptkb:RD-108_engines
|
gptkbp:activities
|
inhibits tumor growth
|
gptkbp:affiliated_with
|
gptkb:healthcare_organization
|
gptkbp:analyzes
|
investigational drug
|
gptkbp:approves
|
not yet approved
|
gptkbp:author
|
gptkb:Dr._Ivan_Petrov
|
gptkbp:class
|
gptkb:drug
|
gptkbp:clinical_trial
|
gptkb:Russia
Phase II
Phase I
promising
|
gptkbp:collaborations
|
gptkb:international_collaboration
|
gptkbp:composed_of
|
gptkb:chemical_compound
|
gptkbp:developed_by
|
Russian scientists
|
gptkbp:discovered_by
|
1960s
|
gptkbp:dissolved
|
soluble in water
soluble in ethanol
|
gptkbp:ecological_role
|
antitumor
|
gptkbp:environmental_impact
|
low toxicity
|
gptkbp:financial_performance
|
stable under normal conditions
|
gptkbp:future_plans
|
ongoing studies
|
https://www.w3.org/2000/01/rdf-schema#label
|
RD-109
|
gptkbp:ingredients
|
C12 H14 N2 O3 S
|
gptkbp:interacts_with
|
none reported
|
gptkbp:invention
|
patented
Pharmaceutical Company X
|
gptkbp:investment
|
oncology drugs
high potential
|
gptkbp:is_tested_for
|
conducted
|
gptkbp:manager
|
intravenous
|
gptkbp:market
|
not available
|
gptkbp:pharmacokinetics
|
under study
inhibits cell proliferation
|
gptkbp:produced_by
|
experimental
|
gptkbp:products
|
IND-123456
RD-114
|
gptkbp:project
|
clinical trials
|
gptkbp:publishes
|
gptkb:Journal_of_Cancer_Research
|
gptkbp:receives_funding_from
|
government grants
|
gptkbp:regulatory_compliance
|
pending
|
gptkbp:research
|
positive results
|
gptkbp:research_areas
|
gptkb:Moscow_Institute_of_Physics_and_Technology
|
gptkbp:research_focus
|
oncology
|
gptkbp:safety_features
|
under evaluation
|
gptkbp:side_effect
|
fatigue
nausea
hair loss
|
gptkbp:social_structure
|
contains a sulfonamide group
|
gptkbp:targets
|
gptkb:healthcare_organization
cancer cells
|
gptkbp:type_of
|
123456-78-9
|
gptkbp:used_in
|
gptkb:healthcare_organization
|
gptkbp:weight
|
270.32 g/mol
|